5-({[1-(2,2-dimethylpropanoyloxy)ethoxy]carbonyl}amino)-2-{[1-(4-methylcyclohexyl)-1H-imidazol-4-yl]methyl}valeric acid | 1335138-99-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-({[1-(2,2-dimethylpropanoyloxy)ethoxy]carbonyl}amino)-2-{[1-(4-methylcyclohexyl)-1H-imidazol-4-yl]methyl}valeric acid
• 英文别名: 5-[1-(2,2-Dimethylpropanoyloxy)ethoxycarbonylamino]-2-[[1-(4-methylcyclohexyl)imidazol-4-yl]methyl]pentanoic acid
• CAS: 1335138-99-2
• 化学式: C₂₄H₃₉N₃O₆
• 分子量: 465.59
• InChiKey: MTKDYJGCJYLATD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  33
• 可旋转键数：
  13
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  120
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Cycloalkyl-Substituted Imidazole Derivative
  申请人：Nagata Tsutomu

  公开号：US20130022587A1

  公开（公告）日：2013-01-24

  A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein A represents a C3 to C12 cycloalkyl group which may be substituted by one to three selected from a fluoro group, a hydroxy group, a C1 to C6 alkyl group, etc; R 1 , R 2 , and R 3 each independently represent a hydrogen atom, a fluoro group, or a C1 to C6 alkyl group; R 4 represents a hydrogen atom or a prodrug group; and Y represents —CH 2 —CHR 5 —CH 2 —NHR 6 (wherein R 5 represents a hydrogen atom, a C1 to C6 alkyl group, or a C1 to C6 alkoxy group, and R 6 represents a hydrogen atom or a prodrug group), or the like exhibits excellent TAFIa inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, and the like.

  以下是通式（I）所代表的化合物或其药学上可接受的盐，其中A代表一个C3到C12的环烷基，该环烷基可以被一个到三个选自氟基、羟基、C1到C6烷基等的基团所取代；R1、R2和R3各自独立地代表氢原子、氟基或C1到C6烷基；R4代表氢原子或前药基团；Y代表—CH2—CHR5— —NHR6（其中R5代表氢原子、C1到C6烷基或C1到C6烷氧基，R6代表氢原子或前药基团）等，具有极好的TAFIa抑制活性，是治疗心肌梗死、心绞痛、急性冠状动脉综合征、脑梗死、深静脉血栓形成、肺栓塞等疾病的治疗药物。
• MEDICAL COMPOSITION FOR PROMOTING FIBRINOLYSIS
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP3238721A1

  公开（公告）日：2017-11-01

  It is intended to provide a novel pharmaceutical composition that can promote fibrinolysis. The present invention provides a pharmaceutical composition for the promotion of fibrinolysis, comprising edoxaban or a pharmaceutically acceptable salt thereof, or a hydrate of the compound or the salt. The present invention further provides a pharmaceutical composition for the promotion of fibrinolysis, comprising edoxaban or a pharmaceutically acceptable salt thereof, or a hydrate of the compound or the salt and further comprising a TAFIa inhibitor.

  本发明旨在提供一种可促进纤维蛋白溶解的新型药物组合物。本发明提供了一种促进纤维蛋白溶解的药物组合物，包含埃多沙班或其药学上可接受的盐，或该化合物或该盐的水合物。本发明进一步提供了一种促进纤维蛋白溶解的药物组合物，该组合物包含埃多沙班或其药学上可接受的盐，或该化合物或盐的水合物，并进一步包含TAFIa抑制剂。
• CYCLOALKYL-SUBSTITUTED IMIDAZOLE DERIVATIVE
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP2548871B1

  公开（公告）日：2017-07-19
• PHARMACEUTICAL COMPOSITION FOR PROMOTION OF FIBRINOLYSIS
  申请人：Daiichi Sankyo Company, Limited

  公开号：US20170368037A1

  公开（公告）日：2017-12-28

  It is intended to provide a novel pharmaceutical composition that can promote fibrinolysis. The present invention provides a pharmaceutical composition for the promotion of fibrinolysis, comprising edoxaban or a pharmaceutically acceptable salt thereof, or a hydrate of the compound or the salt. The present invention further provides a pharmaceutical composition for the promotion of fibrinolysis, comprising edoxaban or a pharmaceutically acceptable salt thereof, or a hydrate of the compound or the salt and further comprising a TAFIa inhibitor.
• THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASES
  申请人：DAIICHI SANKYO COMPANY, LIMITED

  公开号：US20190117624A1

  公开（公告）日：2019-04-25

  A therapeutic agent for inflammatory bowel diseases comprising as an active ingredient a compound represented by the formula (I) wherein R represents a hydrogen atom or a [1-(isobutyryloxy)ethoxy]carbonyl group or the like, or a pharmacologically acceptable salt thereof.